Trulieve Cannabis Corp.

TRLV Healthcare Drug Manufacturers Specialty & Generic

Trulieve Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, roughly unchanged from fiscal 2024.

Revenue
−20.1%
EPS
−2,391.1%
Free cash flow
+24.5%
Total debt
−37.0%

Quarter to September 2026, against a year earlier

11.10 0.20 +1.83%
Market cap
$2.1B
P/E
0.0×
Fwd P/E
−5.6×
Dividend yield
—
F-score
6/9
Altman Z
0.98
Beneish M
−2.99
Dividend safety
n/a

Trulieve Cannabis Corp. (TRLV) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Trulieve Cannabis Corp. (TRLV) trades at a P/B ratio of 2.8×. Over the past ten years it has ranged from 0.0× (December 2021) to 3.2× (September 2026); the current reading is higher than 98% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 1.8× and above the Healthcare sector median of 2.3×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2025 1.5× 84.62%
FY2024 0.8× 13.83%
FY2023 0.7× (2.51%)
FY2022 0.7× (57.94%)
FY2021 1.7× —
FY2020 0.0× —

Quarterly newest first

Period P/B ratio Change
Sep 2026 2.7× 10.20%
Jun 2026 2.5× 163.63%
Mar 2026 0.9× (35.50%)
Dec 2025 1.5× 11.93%
19 more quarters

Against its own ten years

Low 0.0× High 3.2×
Ten-year median 1.0×
Current reading's percentile 98

P/B ratio against peers

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on TRLV